Holen Sie sich die Stockscreener-App
68.92
2.87%
-2.04
Xenon Pharmaceuticals Inc Aktie (XENE) Neueste Nachrichten
Understanding the Setup: (XENE) and Scalable Risk - Stock Traders Daily
Xenon Pharmaceuticals outlines epilepsy focus as pipeline advances - ad-hoc-news.de
Xenon Pharmaceuticals stock hits all-time high at 63.96 USD - Investing.com
Xenon Pharmaceuticals stock hits all-time high at 63.96 USD By Investing.com - Investing.com Canada
XENEXenon Pharmaceuticals Inc Latest SEC Filings - Finviz
Earnings Flash (XENE) Xenon Pharmaceuticals Posts Q1 Per Share Loss $1.17, vs. FactSet Est of Loss $1.18 - marketscreener.com
Xenon Pharmaceuticals faces earnings test as launch nears By Investing.com - Investing.com Nigeria
Price to book forward of Xenon Pharmaceuticals Inc. – NASDAQ:XENE - TradingView
Xenon Pharmaceuticals to present azetukalner epilepsy data at AAN - Investing.com
We're Not Very Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Rate - Moomoo
Xenon Pharmaceuticals stock gains 22% in six months: Here's why - MSN
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Xenon awards new hires 20,200 options and 11,850 RSUs - Stock Titan
Enterprise value to EBIT forward of Xenon Pharmaceuticals Inc. – NASDAQ:XENE - TradingView
Analyst Warns Biohaven's Lead Drug May Struggle To Stand Out - Sahm
The Technical Signals Behind (XENE) That Institutions Follow - Stock Traders Daily
Xenon Pharmaceuticals Inc. Actuals & Estimates (FWB:XP0) - TradingView
Xenon Pharmaceuticals Inc (XENE) Institutional Confidence - TradingKey
Xenon Pharmaceuticals Stock Gains 22% in Six Months: Here's Why - sharewise.com
Xenon Pharmaceuticals (XENE) Q4 2025 earnings summary - Quartr
Xenon Pharmaceuticals Inc. (XENE) Surges Over 3.8% as Stock Tests Key Resistance LevelsOption Breadth - dars.gov.et
Xenon Pharmaceuticals Inc (XENE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Xenon Pharmaceuticals StockLong-term strategy and epilepsy pipeline in focus - Ad-hoc-news.de
Precision Trading with Xenon Pharmaceuticals Inc. (XENE) Risk Zones - Stock Traders Daily
Xenon Pharmaceuticals Inc (XENE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Xenon Pharmaceuticals Inc (XENE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Xenon Pharmaceuticals Inc (XENE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Xenon Pharmaceuticals Inc (XENE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Xenon Pharmaceuticals Inc (XENE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Xenon Pharmaceuticals Inc (XENE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Xenon Pharmaceuticals Inc (XENE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Xenon Pharmaceuticals (XENE) 2026 Bloom Burton & Co. Healthcare Investor Conference summary - Quartr
Assessing Xenon Pharmaceuticals (XENE) Valuation After Recent Share Price Pullback And Modest Undervaluation Estimate - Yahoo Finance
Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight - GlobeNewswire Inc.
Fiera Capital Corp Boosts Stock Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals (XENE) director Cannon sells 1,190 shares under 10b5-1 tax plan - Stock Titan
Xenon (XENE) director Patou sells 1,322 shares in tax-related 10b5-1 trade - Stock Titan
[144] Xenon Pharmaceuticals Inc. SEC Filing - Stock Titan
Xenon Pharmaceuticals (XENE) director receives new RSUs, options and RSU vesting - Stock Titan
Xenon Pharmaceuticals (XENE) director awarded RSUs, options and exercises vested RSUs - Stock Titan
Xenon Pharmaceuticals (XENE) director receives RSUs, options and nets vested shares - Stock Titan
Xenon Pharmaceuticals (XENE) investors approve 2026 equity plan and pay votes - Stock Titan
Xenon (XENE) director receives RSUs, options and adds common shares - Stock Titan
Xenon Q1 earnings match estimates, pipeline development in focus - MSN
Xenon Pharmaceuticals Inc. Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Xenon Pharmaceuticals Inc. Rings the Opening Bell - Nasdaq
Wells Fargo Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $69 - Moomoo
Xenon Pharmaceuticals reports inducement grants under Nasdaq Listing Rule - marketscreener.com
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule - TradingView
XENE Q1 2026 Earnings: EPS Beat Amid Continued Clinical Development FocusOne-Time Gain Impact - newsline.com
J.P. Morgan Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Raises Target Price to $82 - Moomoo
XENE Maintains Overweight Rating -- Price Target Raised to $82.0 - GuruFocus
Xenon Pharmaceuticals (XENE) Edges Higher Amidst Neutral TradingFactor ETF Flow - thelegaladvocate.com
Trading the Move, Not the Narrative: (XENE) Edition - Stock Traders Daily
Xenon Pharmaceuticals (XENE) Holds Near Support Amid Modest PullbackVolatility Skew - thelegaladvocate.com
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):